EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase IV)Open Access · CC BY-NC 4.0

Progesterone Vaginal Gel or Combined Medication for Luteal-Phase Support of Frozen-Thawed Embryo Transfer Cycles: A Single-Centre, Chinese, Randomized, Open-Label, Pilot Study

Rui Yang, Ningning Pan, Xiumei Zhen, Yanhong Fan, Jianhuai Zheng, Yuanyuan Wang, Qiao Liu, Xun Liao, Rui Yang

Gynecologic and Obstetric Investigation · 2025

DOI: 10.1159/000544065 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Gynecologic and Obstetric Investigation, 2025. Verfasst von Rui Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Peking University Third Hospital Beijing, Beijing, China, pnn1210@126.com. Hauptthemen laut MEDLINE: Progesterone, Embryo Transfer, Luteal Phase, Progestins. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study aimed to explore potential differences in efficacy between vaginal progesterone (VPG) and VPG + oral progesterone (OPG) for luteal-phase support in hormone replacement therapy-frozen embryo transfer (HRT-FET) cycles.

Design

A single-centre, open-label, randomized controlled, phase IV pilot study was conducted. Participants/Materials, Setting, Methods: Infertile women aged 20–38 years undergoing HRT-FET cycles were included. Participants were randomized to VPG (n = 86) or VPG + OPG (n = 86). The primary efficacy endpoint was ongoing pregnancy at 10–12 weeks. Secondary efficacy endpoints included β-human chorionic gonadotropin (β-hCG) positivity, implantation rate, and clinical-pregnancy rate. Safety analyses included adverse events (AE) and vital signs.

Results

A higher ongoing pregnancy rate was observed with VPG + OPG (29.1%) versus VPG (18.8%); treatment difference 8.4% (90% confidence interval [CI] −2.2%, 19.0%). Numerical differences also favoured VPG + OPG over VPG for β-hCG positivity (0.9% [90% CI: −10.8%, 12.7%]), implantation (10.4% [90% CI: 0.5%, 21.3%]), and clinical pregnancy (10.1% [90% CI: −0.8%, 21.1%]). Incidences of treatment-emergent AEs were comparable.

Limitations

The single-centre study was limited by a relatively small sample size which could have impacted the reported outcomes. Another limitation was the open-label design, which might have increased the risk of bias for subjective endpoints, such as AE reporting.

Conclusions

A higher ongoing pregnancy rate was observed with VPG + OPG vs VPG; however, a statistical conclusion cannot be reached considering the small sample size. These data suggest that a minimum daily progesterone dose, such as VPG 90 mg + OPG 20 mg reported here, or VPG 180 mg reported in other studies, may be required for successful outcomes following HRT-FET cycles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProgesteroneEmbryo TransferLuteal PhaseProgestinsInfertility, FemaleHumansFemalePilot ProjectsAdultPregnancyPregnancy RateVaginal Creams, Foams, and JelliesAdministration, IntravaginalChinaCryopreservationYoung AdultAdministration, OralEmbryo ImplantationEast Asian People

Stichwörter der Autor:innen

AssistedEmbryo transferInfertilityLuteal phaseProgesteroneReproductive techniques

Substanzen

ProgesteroneVaginal Creams, Foams, and JelliesProgestins

Autor:innen und Institutionen

  • Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Peking University Third Hospital Beijing, Beijing, China, pnn1210@126.com.
  • National Clinical Research Centre for Obstetrics and Gynaecology, Peking University Third Hospital Beijing, Beijing, China, pnn1210@126.com.
  • Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Peking University Third Hospital Beijing, Beijing, China.
  • National Clinical Research Centre for Obstetrics and Gynaecology, Peking University Third Hospital Beijing, Beijing, China.
  • Medical Affairs, Merck Serono Co. Ltd., Beijing, China.

Zitieren

APA

Yang, R., Pan, N., Zhen, X., Fan, Y., Zheng, J., Wang, Y., Liu, Q., Liao, X., & Yang, R. (2025). Progesterone Vaginal Gel or Combined Medication for Luteal-Phase Support of Frozen-Thawed Embryo Transfer Cycles: A Single-Centre, Chinese, Randomized, Open-Label, Pilot Study. Gynecologic and Obstetric Investigation. https://doi.org/10.1159/000544065

Vancouver

Yang R, Pan N, Zhen X, Fan Y, Zheng J, Wang Y, et al. Progesterone Vaginal Gel or Combined Medication for Luteal-Phase Support of Frozen-Thawed Embryo Transfer Cycles: A Single-Centre, Chinese, Randomized, Open-Label, Pilot Study. Gynecologic and Obstetric Investigation. 2025. doi:10.1159/000544065

BibTeX
@article{Yang2025,
  author = {Yang, Rui and Pan, Ningning and Zhen, Xiumei and Fan, Yanhong and Zheng, Jianhuai and Wang, Yuanyuan and Liu, Qiao and Liao, Xun and Yang, Rui},
  title = {Progesterone Vaginal Gel or Combined Medication for Luteal-Phase Support of Frozen-Thawed Embryo Transfer Cycles: A Single-Centre, Chinese, Randomized, Open-Label, Pilot Study},
  journal = {Gynecologic and Obstetric Investigation},
  year = {2025},
  doi = {10.1159/000544065}
}
Kostenlos starten →